Evidence map›Paper›PMID 30367231›Full record

ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2019

[Baseline diagnostics and initial treatment decision for anti-vascular endothelial growth factor treatment in retinal diseases : Comparison between results by study physician and reading centers (ORCA/OCEAN study)].

Christian K Brinkmann, Petrus Chang, Tina Schick, Britta Heimes, Jessica Vögeler, Birgit Haegele, Bernd Kirchhof, Frank G Holz, Daniel Pauleikhoff, Focke Ziemssen and 3 more

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Clinically applicable deep learning-based decision aids for treatment of neovascular AMD.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022
    Article
  3. [Avoiding mistakes in anti-VEGF intravitreal injection therapy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2022
    Article
  4. Observational
  5. Observational
  6. [IVOM quality assurance in Westfalen-Lippe : Structure of quality assurance and results of the pilot study Q-VERA].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Review
  7. [Experienced quality assurance in the IVOM structural contract of the AOK‑BW : A practical example].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Review
  8. [Value and formats of quality assurance : Ophthalmology and intravitreal therapy between reality and wishful thinking].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Review
  9. [Legal aspects of quality assurance : Example of operative intravitreal injection therapy].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2020
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Christian K BrinkmannGRADE Reading Center, Universitäts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland.
Petrus ChangGRADE Reading Center, Universitäts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland.
Tina SchickCologne Image Reading Center, Zentrum für Augenheilkunde, Uniklinik Köln, Köln, Deutschland.
Britta HeimesM3 Reading Center, Augenzentrum, St. Franziskus Hospital, Münster, Deutschland.
Jessica VögelerNovartis Pharma GmbH Nürnberg, Nürnberg, Deutschland.
Birgit HaegeleNovartis Pharma GmbH Nürnberg, Nürnberg, Deutschland.
Bernd KirchhofCologne Image Reading Center, Zentrum für Augenheilkunde, Uniklinik Köln, Köln, Deutschland.
Frank G HolzGRADE Reading Center, Universitäts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland.
Daniel PauleikhoffM3 Reading Center, Augenzentrum, St. Franziskus Hospital, Münster, Deutschland.
Focke ZiemssenUniversitäts-Augenklinik Tübingen, Tübingen, Deutschland.
Sandra LiakopoulosCologne Image Reading Center, Zentrum für Augenheilkunde, Uniklinik Köln, Köln, Deutschland.
Georg SpitalM3 Reading Center, Augenzentrum, St. Franziskus Hospital, Münster, Deutschland.
Steffen Schmitz-ValckenbergGRADE Reading Center, Universitäts-Augenklinik Bonn, Ernst-Abbe-Str. 2, 53127, Bonn, Deutschland. steffen.schmitz-valckenberg@ukbonn.de.
Universitäts-Augenklinik Bonn · DECentrum für Integrierte Onkologie · DESt. Franziskus Hospital · DENovartis (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ORCA module of the non-interventional OCEAN study investigated the use of retinal imaging diagnostics in the clinical treatment of patients undergoing vascular endothelial growth factor (VEGF) inhibitor treatment as part of routine clinical care. This article analyzes the agreement between the diagnosis documented by the treating ophthalmologist and the evaluation of reading centers at baseline as well as the effect on the response to treatment during the course.

methodsA total of 396 patients (age 75.4 years) were enrolled in which ranibizumab treatment was indicated by the treating ophthalmologist due to either diabetic macular edema (DME), neovascular age-related macular degeneration (nvAMD) or retinal venous occlusion (RVO). Over a period of 24 months, patient and examination data, treatments and interpretation of retinal imaging data by the treating ophthalmologist were systematically recorded. Furthermore, retinal imaging data were also evaluated by three reading centers.

resultsIn 338 out of 396 (85.4%) study eyes, the baseline diagnosis of the treating ophthalmologist was confirmed by the reading centers (DME 87.5%, nvAMD 82.3%, RVO 94.9%). In 17 of the remaining 58 eyes with a discrepant diagnosis, there was at least a consensus with respect to the indications for VEGF inhibitor therapy. The differential diagnoses included a variety of different retinal diseases. During follow-up of up to 3 months, eyes with a consistent diagnosis showed a clear increase in visual acuity (6.4 versus 2.7 letters, p = 0.05) and greater decrease in central retinal thickness (-112.3 versus -24.4 μm, p < 0.0001). DISCUSSION: The initial treatment decision for anti-VEGF therapy with consideration of the differential diagnoses can be challenging. Accurate evaluation of the clinical and imaging findings along with appropriate expertise appear to be important. The observation of superior initial response in eyes with a consensus of the diagnosis at baseline underlines the relevance of an adequate initial assessment for a successful treatment outcome.

Indexed as

Retinal DiseasesAngiogenesis InhibitorsHumansIntravitreal InjectionsRanibizumabReadingTomography, Optical CoherenceVascular Endothelial Growth Factor AAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AAge-related macular degenerationDiabetic macular edemaOptical coherence tomographyQuality assuranceRetinal vein occlusion

Identifiers

PMID30367231
OpenAlexW2898513691

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.